High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis
- 22 October 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (5) , 1064-1071
Abstract
Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ∼60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms ‘CHOP’, ‘lymphoma’ and ‘randomized trials’. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m2/week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71–0.96], event-free survival (SHR 0.86; 95% CI 0.75–0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67–0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.Keywords
This publication has 23 references indexed in Scilit:
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2006
- Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countriesBlood Cells, Molecules, and Diseases, 2004
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLBlood, 2004
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLBlood, 2004
- Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphomaBlood, 2003
- CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trialBlood, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphomaAnnals of Oncology, 1997
- A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyAnnals of Oncology, 1994
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.Journal of Clinical Oncology, 1990